A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
Status:
NOT_YET_RECRUITING
Trial end date:
2024-10-20
Target enrollment:
Participant gender:
Summary
The study is an open-label, Tolvaptan-controlled Phase I study to evaluate the safety, tolerability, PK/PD profile and efficacy of HRS-9057 in the treatment of heart failure with volume overload. A total of 24 subjects who experience volume overload due to heart failure despite diuretic treatment will be enrolled in the study and receive HRS-9057 injection or Tolvaptan tablets.